FDA Archives - Page 86 of 220

3 minute read

Precigen Presents Preclinical Data For The Next Generation Mesothelin UltraCAR-T With Intrinsic PD-1 Blockade At The AACR Annual Meeting 2023

April 17, 9:03 AM

– First preclinical data presented for the next generation of the UltraCAR-T platform utilizing a mesothelin (MSLN) chimeric antigen receptor (CAR) – – MSLN is overexpressed on multiple solid

PGEN

3 minute read

IN8bio Announces Preclinical Data For Gamma-Delta CAR Platform And Launches New CD33 Program At AACR Annual Meeting 2023

By Happy Mohamed

April 17, 9:02 AM

INB-300, a gamma-delta T cell chimeric antigen receptor (CAR) platform, demonstrated the ability to target cancer cells while sparing healthy tissue when both express the CAR-targeted antigen. CAR platform

INAB

4 minute read

GeoVax Announces Expansion Of Next-Generation COVID-19 Vaccine Rights To Include Omicron Variants And Use Against Orthopoxviruses

By Happy Mohamed

April 17, 9:01 AM

Expanded Rights Include Development of GEO-CM04S1 Against Mpox (Monkeypox) and Smallpox ATLANTA, GA, April 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology

GOVX

2 minute read

Reported Ealier, Cellectis Presents Preclinical Data On TALEN-Edited MUC1 CAR T-Cells To Enhance Efficacy In Targeting Triple Negative Breast Cancer At The American Association For Cancer Research Annual Meeting

By Happy Mohamed

April 17, 8:46 AM

Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today released preclinical data on

CLLS

2 minute read

Humanigen’s Lenzilumab Being Studied As A Potential First Treatment In Thirty Years With A Novel Mechanism Of Action For Chronic Myelomonocytic Leukemia (CMML), An Orphan Form Of Leukemia

By Happy Mohamed

April 14, 12:07 PM

CMML is an aggressive, poorly understood cancer; approximately 20% of patients survive three years from diagnosis Eleven subjects dosed with lenzilumab and with current standard of care, azacitidine

HGEN

1 minute read

FDA Asks For Additional Successful Trial To Approve Soligenix’s Rare Cancer Candidate

By Vandana Singh

April 14, 11:39 AM

Soligenix Inc (NASDAQ:SNGX) convened a Type A Meeting with the FDA, discussing the contents of a refusal to file (RTF)…

SNGX

3 minute read

EXCLUSIVE: Ketamine Therapy Leaders Share Bold Vision For Future At Benzinga’s Psychedelics Capital Conference

By Lara Goldstein

April 14, 11:36 AM

At the second edition of Benzinga’s Psychedelics Capital Conference, held in sunny Miami, leaders from four major ketamine therapy companies shared their optimistic insights and guidance about the industry.

RVLWF

4 minute read

Merus Announces Publication Of An Abstract On Petosemtamab Monotherapy In Previously Treated Head And Neck Squamous Cell Carcinoma For Plenary Session Oral Presentation At The AACR Annual Meeting 2023 And Provides A Program And Regulatory Update

By Happy Mohamed

April 14, 11:12 AM

- Robust 36% overall response rate (ORR) in 42 evaluable patients - 6 months median duration of response with 17 patients still on treatment as of Nov. 28, 2022 data cutoff - End-of-Phase meeting with

MRUS

5 minute read

Big Bank’s Big Q1 Performance, Florida Gov. Quietly Slips 6-Week Abortion Ban Into Law, Subway Sandwich Seeks $10B Sale: Today’s Top Stories

By Vandana Singh

April 14, 10:01 AM

Benzinga

AMZN

1 minute read

FDA Strikes Down Eli Lilly’s Application Seeking Approval For Ulcerative Colitis Drug

By Vandana Singh

April 14, 9:33 AM

The FDA has issued a complete response letter for Eli Lilly And Co’s (NYSE:LLY) mirikizumab biologic license application (BLA) for ulcerative colitis…

ABBV